Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: IQBAL LATIF who wrote (39633)	5/11/2001 9:05:37 AM
From: IQBAL LATIF	Read Replies (1) \| Respond to of 50167

Shares in Swiss drugs company Novartis AG rose on Friday on news that its cancer drug Gleevec had won fast-track U.S. regulatory approval, raising investor hopes that its robust research pipeline has delivered a blockbuster.

To: IQBAL LATIF who wrote (39633)	5/11/2001 12:26:53 PM
From: Luce Wildebeest	Read Replies (2) \| Respond to of 50167

"My take is the following, Initially the market will think that this kind of spending is not good for the rate cuts and may test the 1228 area but when realisation sinks in that rate cuts are not the goal the goal is revival and if revival cannot be celebrated than someone else will pick the cherries and on that count the market will rebound from that 1246-48 area to go higher and close above that 1268 ideally that will be my call." Ike I had to laugh when I read that. It's so simple and beautifully true. Ironic as well. Who cares about rate cuts if the economy is recovering?